The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
- PMID: 17187906
- DOI: 10.1016/j.vaccine.2006.10.033
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
Abstract
The identification of new adjuvants is a critical need in vaccinology. In this work, it is demonstrated that bis-(3',5')-cyclic dimeric guanosine monophosphate (cdiGMP) exhibits potent adjuvant properties. Subcutaneous co-administration of cdiGMP with beta-galactosidase (beta-Gal) to mice resulted in the elicitation of significantly higher antigen-specific serum IgG titres than in animals receiving beta-Gal alone. Strong cellular immune responses, which were characterized by a balanced Th1/Th2 pattern, were also observed in response to the beta-Gal protein and a peptide encompassing its MHC class I-restricted epitope in immunized animals. These results suggest that cdiGMP represents a promising adjuvant for vaccine development.
Similar articles
-
Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.Vaccine. 2011 Jul 18;29(32):5210-20. doi: 10.1016/j.vaccine.2011.05.026. Epub 2011 May 25. Vaccine. 2011. PMID: 21619907
-
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.Clin Vaccine Immunol. 2007 Aug;14(8):952-8. doi: 10.1128/CVI.00119-07. Epub 2007 Jun 13. Clin Vaccine Immunol. 2007. PMID: 17567766 Free PMC article.
-
Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization.Gene Ther. 2004 Jul;11(13):1048-56. doi: 10.1038/sj.gt.3302261. Gene Ther. 2004. PMID: 15085174
-
The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant.Vaccine. 2010 Apr 19;28(18):3080-5. doi: 10.1016/j.vaccine.2010.02.081. Epub 2010 Mar 1. Vaccine. 2010. PMID: 20197136 Review.
-
Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria?Curr Opin Microbiol. 2004 Apr;7(2):185-91. doi: 10.1016/j.mib.2004.02.007. Curr Opin Microbiol. 2004. PMID: 15063857 Review.
Cited by
-
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.J Clin Invest. 2015 Jun;125(6):2532-46. doi: 10.1172/JCI79915. Epub 2015 May 4. J Clin Invest. 2015. PMID: 25938786 Free PMC article.
-
Monocyte-Derived Dendritic Cells (moDCs) Differentiate into Bcl6+ Mature moDCs to Promote Cyclic di-GMP Vaccine Adjuvant-Induced Memory TH Cells in the Lung.J Immunol. 2021 May 1;206(9):2233-2245. doi: 10.4049/jimmunol.2001347. Epub 2021 Apr 19. J Immunol. 2021. PMID: 33879579 Free PMC article.
-
Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization.Front Immunol. 2017 Dec 12;8:1772. doi: 10.3389/fimmu.2017.01772. eCollection 2017. Front Immunol. 2017. PMID: 29312305 Free PMC article.
-
B Cell-Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses.J Immunol. 2018 Nov 1;201(9):2641-2653. doi: 10.4049/jimmunol.1701405. Epub 2018 Oct 3. J Immunol. 2018. PMID: 30282750 Free PMC article.
-
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7. Cell Rep. 2015. PMID: 25959818 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous